Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Vaccines in development 2013
    Vaccines in development for 2013  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.